Theratechnologies Inc
TSX:TH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Theratechnologies Inc
Net Change in Cash
Theratechnologies Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Theratechnologies Inc
TSX:TH
|
Net Change in Cash
-$21.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Net Change in Cash
CA$77.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
155%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Change in Cash
-$3.2m
|
CAGR 3-Years
71%
|
CAGR 5-Years
37%
|
CAGR 10-Years
15%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Net Change in Cash
$56.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Net Change in Cash
CA$47.5m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Net Change in Cash
-$122.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
Glance View
Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).
See Also
What is Theratechnologies Inc's Net Change in Cash?
Net Change in Cash
-21.7m
USD
Based on the financial report for May 31, 2025, Theratechnologies Inc's Net Change in Cash amounts to -21.7m USD.
What is Theratechnologies Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-20%
The average annual Net Change in Cash growth rates for Theratechnologies Inc have been 5% over the past three years , -20% over the past five years .
